Cannabis Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Expanding adult-use and medical legalization

Delaware began legal adult-use marijuana and marijuana product sales to adults aged 21 and over at licensed retailers on August 1, 2025.^[1] The initial phase used existing medical marijuana compassion centers transitioning into combined medical and adult-use operations. This broadens the eligible customer base through an established licensed route, giving suppliers an additional legally permitted destination for their products. For suppliers already serving those medical outlets, adult consumers become an added buyer group at the same points of sale.

Rising prescription use for chronic pain and neurological symptoms

Germany’s health ministry reported that statutory health-insurance prescriptions for medical cannabis rose by a single-digit percentage in H1 2025 versus H1 2024. Growth in this reimbursed channel creates additional prescription demand for suppliers serving insured care. Germany authorized Vertanical GmbH’s prescription-only Exilby cannabis-flower extract on May 30, 2026, as monotherapy for adults with chronic lower-back pain with a radicular (neuropathic) component. That authorization creates an indication-specific product opportunity within the medical supply system. Prior non-opioid analgesic treatment failure or intolerance confines Exilby’s commercial opening to patients at that defined stage of care.

Product innovation in edibles, beverages, and precision-dose formats

Edible innovation creates a commercial opening when additional formulations can reach an established base of category buyers. Cronos Group Inc. reported that its Spinach brand held 20.8% of Canada’s edible retail-dollar sales in Q2 2026, based on Hifyre Retail Analytics. The company reported 5 SOURZ gummies among Canada’s top 10 edible products, including the top-selling stock-keeping unit. In July 2026, Cronos expanded its Canadian SOURZ lineup with CBG, CBN, and CBC formulations alongside THC. Existing commercial scale gives such formulation extensions a route through a brand already competing within the edible category.

Premiumization toward high-potency flower and concentrates

Canadian non-certified indoor- and greenhouse-grown bulk wholesale trading shows high-potency flower becoming a volume category. The Canadian Cannabis Exchange reported that 30%+ THC flower rose from 13% of flower trading volume across 2023 and 2024 to 18% in 2025 and 25% year to date through April 2026. Its scarcity premium narrowed as supply caught up with demand. Organigram Global Inc. reported record average THC potency of 30.4% at its Moncton facility in fiscal Q3 2026, ended June 30, 2026. Quarterly harvest exceeded 30,000 kilograms, approximately 25% above the prior-year quarter. Cultivators now compete on delivering 30%+ THC flower at scale, because the scarcity premium that once rewarded potency alone has narrowed.

Banking, tax, and interstate commerce barriers

Financing costs can limit how quickly licensed operators turn demand opportunities into additional product supply. During the US Government Accountability Office’s August 2024 to August 2026 audit, participants in 7 of 8 US focus groups cited lender-offered interest rates above 15%.^[2] Those groups involved 51 cannabis-related business owners and managers, who also described lengthy, resource-intensive searches for funding. Such terms make an expansion harder to finance even where permitted local demand provides a commercial opening. Washington’s 2023 law would permit interstate cannabis-delivery agreements only after federal law permits transfers or a Department of Justice opinion or memorandum allows or tolerates them. Expensive funding and conditional transfer permission leave operators financing local expansion without an assured route to deploy that supply across state borders.

Advertising, packaging, and claims restrictions

Canada’s March 2025 cannabis amendments eased selected requirements but retained core promotion and packaging controls. The government’s rationale identified packaging and labeling restrictions as obstacles to federally licensed businesses competing with illicit suppliers under an unchanged framework. Retained youth-protection controls restrict appealing endorsements and depictions of people, characters, or animals. These constraints limit the visual and promotional tools available to differentiate legal products, making compliance part of brand development. In July 2025, Pure Sunfarms, a wholly owned Village Farms International subsidiary, introduced windowed packaging gradually across its Canadian dried flower formats. Greater product visibility can help a single brand’s dried flower, but retained promotion controls limit legal brands’ communication with potential customers.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Cannabis Market Segment Analysis

Flower accounted for a 42.34% share of the cannabis market size in 2026. Ontario’s Dried Flower category led the province’s legal retail sales in the fiscal year ended March 31, 2025. The Ontario Cannabis Store also reported a declining revenue share for that category as customers diversified their purchases. That combination gives cultivators a substantial existing outlet for flower while exposing them to changing allocations within consumers’ cannabis spending. Vapes and infused pre-rolls compete for Ontario consumers’ spending, so additional flower capacity needs a selling case beyond cultivation scale.

Beverages are the fastest-growing segment, with a CAGR of 14.4% forecast from 2027 to 2032. Verano Holdings Corp. reported that cannabis beverage dispensary sales grew 13% in 2025 across the markets where it operates. Noncarbonated beverages and shots experienced the strongest growth among beverage formats in those markets. Dispensary selling therefore offers manufacturers a defined channel for expansion, while the different format trajectories make product selection commercially significant. Noncarbonated beverages and shots, the formats that grew fastest in those markets, are the logical starting point for a dispensary launch.

Medical use represented a 56.62% cannabis market share in 2026. Germany’s medical-cannabis flower imports were estimated at around 192 metric tons in 2025, 6 times the 2023 volume of 32 metric tons. That import flow illustrates a medical supply route in which growers and processors can serve a national product channel through cross-border trade, connecting external cultivation with medical availability. Growers and processors outside Germany can reach this channel through import supply relationships.

Adult-use/recreational products are the fastest-growing segment, with a CAGR of 14.2% forecast from 2027 to 2032. Massachusetts retailers recorded 46.3 million adult-use transactions in 2025, about 3.4 million more than in 2024, while falling average prices limited the annual sales increase to approximately USD 3 million. Because 3.4 million additional transactions added only about USD 3 million in sales, lower average prices absorbed nearly all of the traffic gain, so adult-use supplier revenue depends on holding price as well as winning volume. Wellness and nutraceutical use has a distinct motivation, with 46% of 384 past-year CBD users aged 18 to 75 surveyed in England, Wales, and Northern Ireland in August 2025 citing general well-being.

THC-dominant products were the largest segment by compound, accounting for 62.89% of the market in 2026. In British Columbia’s 2025 survey, 39% of adult cannabis users reported THC-only use in the prior 12 months, versus 21% CBD-only use, with 77% reporting products containing both. THC-only use provides evidence of a substantial THC-oriented user base alongside mixed-cannabinoid consumption. The leading segment competes for users who also consume mixed-cannabinoid products, so product positioning must address overlapping consumption patterns.

CBD-dominant products are the fastest-growing segment, with a CAGR of 14.2% forecast from 2027 to 2032. Jazz Pharmaceuticals plc reported that net product sales of its cannabidiol medicine Epidiolex/Epidyolex rose 16% year over year to USD 292 million in Q2 2026, which it attributed to continued strong demand. During the same quarter, the company submitted a new drug application for a cannabidiol capsule formulation intended to broaden use within approved indications and increase patient flexibility. An additional dosage form could extend the ways patients receive a medicine without requiring a new therapeutic indication, if the relevant authorization is granted. That makes formulation development a distinct growth lever for medicinal CBD, alongside demand for an established cannabidiol medicine.

Marijuana was the largest segment by source, accounting for 62.17% of the market in 2026. Massachusetts Marijuana Establishments generated more than USD 1.65 billion in adult-use retail sales in 2025. Curaleaf opened dispensaries in Jacksonville Beach and Fernandina Beach in Q2 2026, taking its Florida footprint to 73 and its nationwide operated and managed footprint to 174. The new Florida outlets add places for legally supplied marijuana products to reach consumers, linking this source’s commercial expansion to retail coverage alongside crop availability.

Hemp is the fastest-growing segment, with a CAGR of 14.6% forecast from 2027 to 2032. US industrial floral hemp production grown in the open was estimated at 33.2 million pounds in 2025, up 60% from 2024. For makers of hemp-derived cannabinoid products, agricultural expansion can widen feedstock options without requiring their own cultivation expansion. The commercial opening moves downstream to processors able to convert that larger crop into products for authorized end uses.

Dispensaries were the largest segment by distribution channel, accounting for 58.02% of the market in 2026. Canada had 3,295 legal cannabis retail businesses with employees at the end of 2025. That retail base gives suppliers multiple destinations for legally manufactured products, so expansion can come from serving additional licensed businesses rather than owning every consumer-facing operation. Supplier growth then turns on winning shelf space across a base of thousands of licensed retail businesses.

Online direct-to-consumer is the fastest-growing segment, with a CAGR of 14.1% forecast from 2027 to 2032. Alberta allows licensed retailers with operating physical stores to sell online after endorsement by Alberta Gaming, Liquor and Cannabis, with customers ordering and paying directly with the licensee. Canna Cabana’s Calgary store, operating under a license effective May 16, 2025, is authorized for online sales. Delivery services follow a distinct model in California, where non-storefront retailers sell only through delivery and storefront retailers may also deliver. Alberta’s online opportunity belongs to endorsed physical-store operators selling directly to customers, linking digital expansion to an existing licensed retail operation.

Geography Analysis

North America Cannabis Market

North America accounted for a 72.89% share of the cannabis market size in 2026. New Jersey’s cannabis industry generated more than USD 1.16 billion in sales in 2025. Across 30 US states and the District of Columbia, estimated cannabis excise-tax receipts reached USD 3.55 billion from July 2025 to June 2026. These sales and tax bases illustrate regulated activity across individual jurisdictions, giving suppliers multiple destinations within an established regional business base. With US interstate transfers still conditional on federal action, North America’s leading position includes separately supplied state markets rather than one national US channel.

Asia-Pacific Cannabis Market

Asia-Pacific is the fastest-growing geography, with a CAGR of 14.5% forecast from 2027 to 2032. Australian Office of Drug Control figures reported by IgniteIt put cannabis imports at 81,119 kilograms in 2025, an increase of nearly 5% from 77,406 kilograms in 2024. Australian production also rose 30% to 55,337 kilograms in 2025, adding a domestic supply expansion to the country’s cross-border product flows. Exporters entering Australia face domestic growers whose production expanded faster than import volumes in 2025, increasing the local supply available alongside imported products.

South America includes Uruguay’s cannabis social clubs, which supply herbal cannabis to registered members under a 45-member cap per club. In Europe, Malta’s February 2026 rules limit cannabis stocks at approved member-distribution sites by permit category, with packaging and seals set by the regulator. In the Middle East, Israeli Ministry of Health data cited by IM Cannabis recorded 143,900 medical patients in May 2026, including 110,900 license holders and 33,000 prescription holders. Africa’s cultivation base includes Morocco’s Chefchaouen province, where 1,417 farmers participated in licensed cannabis cultivation covering 1,341 hectares in 2025, according to the interior minister’s figures reported by Hespress. These routes create different limits on scale, with member-only distribution, medical access, and licensed cultivation defining distinct paths for product supply and commercial participation.

Regulatory Framework and Outlook

This comparison covers selected jurisdictions from the perspective of a licensed commercial medicinal-cannabis product supplier. Cultivation permission, product authorization, and sales channels to patients create separate commercial gates, making the availability of an authorized medical route central to policy attractiveness. The US column separates the specified medical Schedule III order from the broader rescheduling proposal, while Germany’s medical permissions are distinct from its noncommercial adult-cultivation framework.

The September 29, 2026 stay of broader US rescheduling left April’s specified medical order unchanged, supporting continuity at low attractiveness, while Colombia’s broader national-use/export route and localized March 2026 proposal support higher attractiveness and continuity. Germany has an established licensed medical trade path, but the bill referred in December 2025 would harden initial flower-prescribing and mail-order access if implemented, while Australia’s license-and-permit framework supports medical suppliers, and the September 2026 intention to make only minor or necessary amendments ahead of the April 1, 2027 regulatory sunset favors continuity. Turkey’s quota, site-permission, contract, and prescription gates are the operative framework, and the Agriculture Ministry’s April 2, 2026 meeting on planned cultivation-regulation changes did not specify which provisions would change, so no easing or hardening is evidenced. South Africa’s SAHPRA license and Department of Health manufacturing permit are the operative medicinal route, and the trade department’s October 2, 2026 statement described the Hemp and Cannabis Master Plan as under review, so no new license or sales route is evidenced.

Value Chain Stages

This comparison traces how licensed cannabis products become saleable stock and where operators earn from production, testing, wholesale distribution, and retail sales. Cresco Labs reported 13 cultivation and production facilities across 8 US states on August 6, 2026, and distributes its branded products to third-party licensed retailers and its own stores. California requires passing batch tests by licensed laboratories before retail transport, destruction or referral of failed goods to a manufacturer for remediation, and quality assurance review by type 11 distributors. That release condition creates a commercial gate between manufacturing and product sales, giving specialized testing a role within an integrated supply chain.

These arrangements give integrated operators control over several selling stages while preserving a distinct commercial role for laboratories providing testing and technical services. Production earns through product transactions, while laboratory services and wholesaling attach revenues to different activities and pricing mechanisms. California’s failed-batch rules place product value at risk before retail sale, even when cultivation and selling belong to the same operator.

Key Opportunities for Market Participants

This comparison examines product-supply opportunities created by Brazil’s 2026 medicinal-cannabis cultivation pathway, from domestic manufacturing inputs to own-crop exports. The medicinal pathway permits legal entities to cultivate varieties with total THC at or below 0.3% after Anvisa grants special authorization and other applicable requirements are met. Eligible manufacturing uses include registered medicines and Anvisa-authorized cannabis products, while medicinal cultivation authorization holders may export their own crop only through the raw plant-material stage under sanitary and customs requirements. Ease Labs Pharma produces cannabidiol and cannabis-extract products in Brazil for the prescription non-compounding pharmacy and drugstore channel.

Brazil’s rules require medicinal and export production estimates to be justified by contracts or documents of intent to buy, sell, or distribute that match declared demand. The intended sales route must therefore be defined when a grower justifies planned cultivation volumes. Documents of intent can establish this demand alignment before a completed supply contract, favoring cultivation proposals developed around prospective medicinal buyers.